Phase II Clinical Study of Pyrotinib in First-line Treatment of Primary HER2-amplified/Mutated Advanced Non-small Cell Lung Cancer

This study is testing whether pyrotinib — a targeted therapy drug — can be used as a first-line treatment for patients with advanced non-small cell lung cancer (NSCLC) that has a HER2 genetic mutation or amplification. Currently, there are limited approved treatments targeting HER2 in lung cancer. **You may be eligible if...** - You are 18 or older with Stage IIIB or IV non-small cell lung cancer - Your cancer has a confirmed HER2 insertion mutation, point mutation, or amplification (found by genetic testing) - You have not had any prior systemic treatment for advanced-stage lung cancer - You have at least one measurable tumor - Your heart function (left ventricular ejection fraction) is at least 50% - Your blood counts, kidney, and liver function are adequate **You may NOT be eligible if...** - Your cancer is HER2-negative or has a different driver mutation treated by another targeted therapy - You have previously received any systemic treatment for advanced lung cancer - You have active brain metastases that are symptomatic or untreated - You have significant heart, kidney, or liver problems Talk to your doctor to see if this trial is right for you.